The therapeutic potential of immuno-cell therapy of cancer in combination with aminobisphosphonates

Anticancer Research

Volumn 26, Issue 6 A, 2006, Pages 3989-3995

  Goto, Shigenori ^a   Noguchi, Atsutaka ^b   Jinguji, Hidemasa ^b   Takahara, Masashi ^b  

^a Seta Clinic   (Japan)

^b MEDINET Co Ltd   (Japan)

Author keywords

Adoptive immunotherapy; Aminobisphosphonates; Gamma delta T lymphocytes; Immuno cell therapy; Review; T cells

Indexed keywords

AMINOBISPHOSPHONIC ACID DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; IMATINIB; INTERLEUKIN 2; OKT 3; PAMIDRONIC ACID; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR DELTA CHAIN; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BONE CANCER; BONE DISEASE; BONE METASTASIS; BONE PAIN; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CELL PROLIFERATION; CELL THERAPY; CLINICAL TRIAL; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; T LYMPHOCYTE; UNIVERSITY HOSPITAL;

COMBINED MODALITY THERAPY; DIPHOSPHONATES; FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MIDDLE AGED; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTES;

EID: 33845956514     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Vetto JT, Seipp CA and Simpson C: A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery 100: 262-272, 1986.
2. Egawa K: Immuno-cell therapy of cancer in Japan. Anticancer Res 24: 3321-3326, 2004.
3. Baba M, Yamaguchi Y and Fujisawa T: The effect of localized therapy with postsurgical local recurrence of lung carcinoma and metastatic lung tumors. Jpn J Cancer Chemother 75: 1342-1350, 1988.
4. Komatsu T, Yamauchi K, Furukawa T and Obata H: Transcatheter arterial injection of autologous lymphokine-activated killer (LAK) cells into patients with liver cancer. J Clin Immunol 10: 167-174, 1990.
5. Usui A: Study on adoptive immunotherapy in patients with renal cell carcinoma. II. Plasmapheresis and adoptive immunotherapy using LAK cells and IL-2 (in Japanese). J Nippon Hinyoukika Gakkai Zasshi 81: 1058-1064, 1990.
6. Yamaguchi Y, Takayama T, Kawami H, Sato Y, Baba N, Kuroi K and Toge T: LAK cell adoptive immunotherapy and its problems, in Japanese Nippon Geka Gakkai Zasshi 92: 1234-1236, 1991.
7. Nakano E, Iwasaki A, Seguchi T, Sugao H, Tada Y, Matsuda M and Sonoda T: Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2. J Japn Soc Urol 82: 395-404, 1991.
8. Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A and Takahashi T: Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with Cisplatin-containing chemotherapy in patients with epithelial cancer. Cancer Res 51: 1934-1939, 1991.
9. Nomura K and Fujioka T: Study of adoptive immunotherapy for metastatic renal cell carcinoma with lymphokine-activated killer cells and Interleukin 2. II Clinical evalluation (in Japanese). J Nippon Hinyoukika Gakkai Zsshi 84: 831-840, 1993.
10. Ibayashi Y, Yamaki T, Kawahara T, Daibo M, Kubota T, Uede T, Tanabe S and Hashi K: Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients. Neurol Med Chir (Tokyo) 33: 448-457, 1993.
11. Haruta I, Yamauch K, Aruga A, Komatsu T, Takasaki K, Hayashi N and Hanyu F: Analytical study of the clinical response to two distinct adoptive immunotherapies for advanced hepatocellular carcinoma: comparison between LAK and CTL therapy. J Immunother 19: 218-223, 1996.
12. Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T and Takahashi K: Adoptive immunotherapy of patients with metastatic renal cell carcinoma using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. Int J Urol 5: 16-21, 1998.
13. Toh U, Yamana H, Sueyoshi S, Tanaka T, Niiya F, Katagiri K, Fujita H, Shirozou K and Itoh K: Locoregional immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 6: 4663-4673, 2000.
14. Goto S, Shirotani N, Hatakeyama M, Tagami C, Arakawa H, Kuwata E, Noguchi K and Egawa K: Clinical benefit of non-toxic therapy in patients with advanced cancer (Opinion). Anicancer Res 22: 2461-2464, 2002.
15. Ebina T, Ogama N, Shimanuki H, Tagami C, Arakawa H, Kuwata E, Noguchi K and Egawa K: Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: Prognostic significance of serum immunosuppressive acid protein levels. Cancer Immunol Immunother 52: 555-560, 2003.
16. Gomez GG, Hutchinson RB and Kruse CA: Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer. Cancer Treat Rev 27: 375-402, 2001.
17. Gold JE, Malamud SC, LaRosa F, Seder R and Osband ME: Adoptive chemoimmunotherapy for the treatment of relapsed and refractory solid tumors using ex vivo activated memory T cells (Autolymphocyte therapy) and cyclophosphamide. J Immunol 13: 213-221, 1993.
18. Kaneko T, Goto S, Kushima Y, Miyamoto Y, Eriguchi M, Nieda M and Egawa K: A report of three patients treated with immunocell therapy with imatinib mesylate. Anticancer Res 24: 3303-3309, 2004.
19. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K and Reitsma DJ: Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16: 2038-2044, 1998.
20. Theriault RL, Lipton A, Hortobagyi GN, Leff R, Gluck S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M and Reitsma DJ: Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 17: 846-854, 1999.
21. Pavlakis N, Schmidt R and Stockler M: Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3: CD003474, 2005.
22. Body JJ and Mancini I: Bisphosphonates for cancer patients: why, how, and when? Support Care Cancer 10: 399-407, 2002.
23. Li EC and Davis LE: Zoledronic acid: a new patenteral bisphosphonate. Clin Ther 25: 2669-2708, 2003.
24. Reitsma PH, Teitelbaum SL, Bijvoet OL and Kahn AJ: Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (C12MDP) on rat macrophage-mediated bone resorption in vitro. J Clin Invest 70: 927-933, 1982.
25. Delaisse JM, Eeckhout Y and Vaes G: Bisphosphonates and bone resorption: effects on collagenase and lysosomal enzyme excretion. Life Sci 37: 2291-2296, 1985.
26. Flanagan AM and Chambers TJ: Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49: 407-415, 1991.
27. Kunzmann V, Bauer E, Feurle J, Weibinger F, Tony HP and Wilhelm M: Stimulation of γδT cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96: 384-392, 2000.
28. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T and Tony HP: γδ T cells for immune therapy of patients with lymphoid malignancies. Blood 102: 200-206, 2003.
29. Casetti R, Perretta G, Taglioni A, Mattei M, Colizzi V, Dieli F, D'Offizi G, Malkovsky M and Poccia F: Drug-induced expansion and differentiation of V gamma 9V delta 2 T cells in vivo: the role of exogenous IL-2. J Immunol 175: 1593-1598, 2005.
30. Hayday A: γδ T cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol 18: 975-1026, 2000.
31. Porcelli S, Brenner MB and Band H: Biology of the human γδ T-cell receptor. Immunol Rev 120: 137-183, 1991.
32. Corvaisier M, Moreau-Aubry A, Diez E, Bennouna J, Mosnier JF, Scotet E, Bonneville M and Jotereau F: Vγ9Vδ2 T Cell Response to Colon Carcinoma Cells. J Immunol 175: 5481-5488, 2005.
33. Kabelitz D, Wesch D, Fitters E and Zoller M: Characterization of tumor reactivity of human V gamma 9V delta 2 gamma delta T cells in vitro and in SCID mice in vivo. J Immunol 173: 6767-6776, 2004.
34. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, Hobby P, Sutton B, Tigelaar RE and Hayday AC: Regulation of cutaneous malignancy by gammadelta T cells. Science 294: 605-609, 2001.
35. Zheng BJ, Chan KW, Im S, Chua D, Sham JS, Tin PC, He ZM and Ng MH. Anti-tumor effects of human peripheral γ δ T cells in a mouse tumor model. Int J Cancer 92: 421-425, 2001.
36. Lozupone F, Pende D, Burgio VL, Castelli C, Spada M, Venditti M, Luciani F, Lugini L, Federici C, Ramoni C, Rivoltini L, Parmiani G, Belardelli F, Rivera P, Marcenaro S, Moretta L and Fais S: Effect of human natural killer and γδ T cells on the growth of human autologous melanoma xenograft in SCID mice. Cancer Res 64: 378-385, 2004.
37. Malkovska V, Cigel FK, Armstrong N, Storer BE and Hong R: Antilymphoma activity of human γ δ T-cells in mice with severe combined immune deficiency. Cancer Res 52: 5610-5616, 1992.
38. Bialasiewicz AA, Ma JX and Richard G: α/β- and γ/δ TCR+ lymphocyte infiltration in necrotising choroidal melanomas. Br J Ophthalmol 83: 1069-1073, 1999.
39. Olive C, Nicol D and Falk MC: Characterisation of γδ T cells in renal cell carcinoma patients by polymerase chain reaction analysis of T cell receptor transcripts. Cancer Immunol Immunother 44: 27-34, 1997.
40. Ferrarini M, Heltai S, Pupa SM, Mernard, S and Zocchi R: Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing γ/δ T-cell receptors. J Natl Cancer Inst 88: 436-441, 1996.
41. Carding SR and Egan PJ: Gammadelta T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2: 336-345, 2002.
42. Groh V, Steinle A, Bauer S and Spies T: Recognition of stress-induced MHC molecules by intestinal epithelial γδ T cells. Science 279: 1737-1740, 1998.
43. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL and Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress inducible MICA. Science 285: 727-729, 1999.
44. Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T and Bukowski JF: MICA engagement by human V γ 2V δ 2 T cells enhances their antigen dependent effector function. Immunity 15: 83-93, 2001.
45. Wu J, Groh V and Spies T: T cell antigen receptor engagement and specificity in the recognition of stress-inducible MHC class I-related chains by human epithelial γδ T cells. J Immunol 169: 1236-1240, 2002.
46. Shipman CM, Rogers MJ, Apperley JF, Russell RG and Croucher PI: Bisphosphonates induce apoptosis in human myeloma cell lines: a novel antitumour activity. Br J Haematol 98: 665-672, 1997.
47. Shipman CM, Croucher PI, Russell RG, Helfrich MH and Rogers MJ: The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res 58: 5294-5297, 1998.
48. Aparicio A, Gardner A, Tu Y, Savage A, Berenson J and Lichtenstein A: In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates. Leukemia 12: 220-229, 1998.
49. Derenne S, Amiot M, Barille S, Collette M, Robillard N, Berthaud P, Harousseau JL and Bataille R: Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res 14: 2048-2056, 1999.
50. Tassone P, Forciniti S, Galea E, Morrone G, Turco MC, Martinelli V, Tagliaferri P and Venuta S: Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14: 841-844, 2000.
51. Kunzmann V, Bauer E and Wilhelm M: γ/δ T-cell stimulation by pamidronate. N Engl J Med 340: 737-738, 1999.
52. Das H, Wang L, Kamath A and Bukowski JF: V γ 2V δ 2 T-cell receptor-mediated recognition of aminobisphosphonates. Blood 98: 1616-1618, 2001.
53. Miyagawa F, Tanaka Y, Yamashita S and Minato N: Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human γδ T cells by aminobisphosphonate antigen. J Immunol 166: 5508-5514, 2001.